{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:45:56Z","timestamp":1790376356264,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L011794\/1"],"award-info":[{"award-number":["MR\/L011794\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L011794\/1"],"award-info":[{"award-number":["MR\/L011794\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L011794\/1"],"award-info":[{"award-number":["MR\/L011794\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L011794\/1"],"award-info":[{"award-number":["MR\/L011794\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L011794\/1"],"award-info":[{"award-number":["MR\/L011794\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Elevated brain glutamate has been implicated in non-response to antipsychotic medication in schizophrenia. Biomarkers that can accurately predict antipsychotic non-response from the first episode of psychosis (FEP) could allow stratification of patients; for example, patients predicted not to respond to standard antipsychotics could be fast-tracked to clozapine. Using proton magnetic resonance spectroscopy (\n                    <jats:sup>1<\/jats:sup>\n                    H-MRS), we examined the ability of glutamate and Glx (glutamate plus glutamine) in the anterior cingulate cortex (ACC) and caudate to predict response to antipsychotic treatment. A total of 89 minimally medicated patients with FEP not meeting symptomatic criteria for remission were recruited across two study sites.\n                    <jats:sup>1<\/jats:sup>\n                    H-MRS and clinical data were acquired at baseline, 2 and 6 weeks. Response was defined as &gt;20% reduction in Positive and Negative Syndrome Scale (PANSS) Total score from baseline to 6 weeks. In the ACC, baseline glutamate and Glx were higher in Non-Responders and significantly predicted response (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.02;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200942). Overall accuracy was greatest for ACC Glx (69%) and increased to 75% when symptom severity at baseline was included in the model. Glutamate metabolites in the caudate were not associated with response, and there was no significant change in glutamate metabolites over time in either region. These results add to the evidence linking elevations in ACC glutamate metabolites to a poor antipsychotic response. They indicate that glutamate may have utility in predicting response during early treatment of first episode psychosis. Improvements in accuracy may be made by combining glutamate measures with other response biomarkers.\n                  <\/jats:p>","DOI":"10.1038\/s41386-022-01508-w","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T07:59:23Z","timestamp":1669881563000},"page":"567-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration"],"prefix":"10.1038","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-064X","authenticated-orcid":false,"given":"Alice","family":"Egerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecila","family":"Casetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-962X","authenticated-orcid":false,"given":"Bill","family":"Deakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-4835","authenticated-orcid":false,"given":"Richard","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kassoumeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Lankshear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shon","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mikulskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Millgate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Oloyede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviv","family":"Segev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra-Verena","family":"Sendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-1018","authenticated-orcid":false,"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"1508_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085\u201397.","journal-title":"Lancet"},{"key":"1508_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","volume":"115","author":"H Boter","year":"2009","unstructured":"Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115:97\u2013103.","journal-title":"Schizophr Res"},{"key":"1508_CR3","first-page":"1","volume":"14","author":"HY Meltzer","year":"1997","unstructured":"Meltzer HY. Treatment-resistant schizophrenia\u2013the role of clozapine. CurrMedResOpin. 1997;14:1\u201320.","journal-title":"CurrMedResOpin"},{"key":"1508_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174:216\u201329.","journal-title":"Am J Psychiatry"},{"key":"1508_CR5","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1017\/S0033291716002014","volume":"46","author":"J Lally","year":"2016","unstructured":"Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231\u201340.","journal-title":"Psychol Med"},{"key":"1508_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1017\/S0033291721000246","volume":"51","author":"K Griffiths","year":"2021","unstructured":"Griffiths K, Millgate E, Egerton A, MacCabe JH. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. Psychol Med. 2021;51:376\u201386.","journal-title":"Psychol Med"},{"key":"1508_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archpsyc.62.9.975","volume":"62","author":"M Marshall","year":"2005","unstructured":"Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975\u201383.","journal-title":"Arch Gen Psychiatry"},{"key":"1508_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s10198-019-01108-4","volume":"20","author":"H Jin","year":"2019","unstructured":"Jin H, McCrone P, MacCabe JH. Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life? Eur J Health Econ. 2019;20:1425\u201335.","journal-title":"Eur J Health Econ"},{"key":"1508_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1177-y","volume":"17","author":"AL Gillespie","year":"2017","unstructured":"Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry. 2017;17:12.","journal-title":"BMC Psychiatry"},{"key":"1508_CR10","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1038\/npp.2012.113","volume":"37","author":"A Egerton","year":"2012","unstructured":"Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 2012;37:2515\u201321.","journal-title":"Neuropsychopharmacology"},{"key":"1508_CR11","doi-asserted-by":"crossref","unstructured":"Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in Schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2013;75:e11-13.","DOI":"10.1016\/j.biopsych.2013.06.011"},{"key":"1508_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/schbul\/sbaa128","volume":"47","author":"A Egerton","year":"2021","unstructured":"Egerton A, Murphy A, Donocik J, Anton A, Barker GJ, Collier T, et al. Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). Schizophr Bull. 2021;47:505\u201316.","journal-title":"Schizophr Bull"},{"key":"1508_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.biopsych.2018.09.009","volume":"85","author":"Y Iwata","year":"2019","unstructured":"Iwata Y, Nakajima S, Plitman E, Caravaggio F, Kim J, Shah P, et al. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry. 2019;85:596\u2013605.","journal-title":"Biol Psychiatry"},{"key":"1508_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/schbul\/sbv151","volume":"42","author":"E Mouchlianitis","year":"2016","unstructured":"Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, et al. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. Schizophr Bull. 2016;42:744\u201352.","journal-title":"Schizophr Bull"},{"key":"1508_CR15","doi-asserted-by":"crossref","unstructured":"Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology. 2019;45:632\u201340.","DOI":"10.1038\/s41386-019-0589-z"},{"key":"1508_CR16","doi-asserted-by":"crossref","unstructured":"Nakahara T, Tsugawa S, Noda Y, Ueno F, Honda S, Kinjo M, et al. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-magnetic resonance spectroscopy studies. Mol Psychiatry. 2022; 27:744\u201357.","DOI":"10.1038\/s41380-021-01297-6"},{"key":"1508_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/jamapsychiatry.2021.0380","volume":"78","author":"K Merritt","year":"2021","unstructured":"Merritt K, McGuire PK, Egerton A, Investigators HMiS, Aleman A, Block W, et al. Association of age, antipsychotic medication, and symptom severity in Schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega-analysis of individual participant-level data. JAMA Psychiatry. 2021;78:667\u201381.","journal-title":"JAMA Psychiatry"},{"key":"1508_CR18","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","volume":"23","author":"A Egerton","year":"2018","unstructured":"Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23:2145\u201355.","journal-title":"Mol Psychiatry"},{"key":"1508_CR19","doi-asserted-by":"publisher","first-page":"110473","DOI":"10.1016\/j.pnpbp.2021.110473","volume":"113","author":"F Reyes-Madrigal","year":"2022","unstructured":"Reyes-Madrigal F, Guma E, Leon-Ortiz P, Gomez-Cruz G, Mora-Duran R, Graff-Guerrero A, et al. Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients. Prog Neuropsychopharmacol Biol Psychiatry. 2022;113:110473.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1508_CR20","doi-asserted-by":"crossref","unstructured":"Bojesen KB, Ebdrup BH, Jessen K, Sigvard A, Tangmose K, Edden RAE, et al. Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naive patients with psychosis. Psychol Med. 2020;50:2182\u201393.","DOI":"10.1017\/S0033291719002277"},{"key":"1508_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-019-0080-1","volume":"5","author":"K Merritt","year":"2019","unstructured":"Merritt K, Perez-Iglesias R, Sendt KV, Goozee R, Jauhar S, Pepper F, et al. Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. NPJ schizophrenia. 2019;5:12.","journal-title":"NPJ schizophrenia"},{"key":"1508_CR22","doi-asserted-by":"publisher","first-page":"553269","DOI":"10.3389\/fpsyt.2020.553269","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Ren H, He Y, Li Z, Ma X, Yuan L, et al. Anterior cingulate cortex glutamate levels are related to response to initial antipsychotic treatment in drug-naive first-episode schizophrenia patients. Front psychiatry. 2020;11:553269.","journal-title":"Front psychiatry"},{"key":"1508_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fpsyt.2017.00066","volume":"8","author":"A Egerton","year":"2017","unstructured":"Egerton A, Bhachu A, Merritt K, McQueen G, Szulc A, McGuire P. Effects of antipsychotic administration on brain glutamate in schizophrenia: a systematic review of longitudinal 1H-MRS sStudies. Front psychiatry. 2017;8:66.","journal-title":"Front psychiatry"},{"key":"1508_CR24","doi-asserted-by":"crossref","unstructured":"Kubota M, Moriguchi S, Takahata K, Nakajima S, Horita N. Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Schizophr Res. 2020;222:122\u201332.","DOI":"10.1016\/j.schres.2020.03.069"},{"key":"1508_CR25","first-page":"119","volume":"8","author":"N Goto","year":"2012","unstructured":"Goto N, Yoshimura R, Kakeda S, Nishimura J, Moriya J, Hayashi K, et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat. 2012;8:119\u201322.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1508_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","volume":"70","author":"C de la Fuente-Sandoval","year":"2013","unstructured":"de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Stephano S, Favila R, Diaz-Galvis L, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA psychiatry. 2013;70:1057\u201366.","journal-title":"JAMA psychiatry"},{"key":"1508_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.biopsych.2017.09.028","volume":"83","author":"C de la Fuente-Sandoval","year":"2018","unstructured":"de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, Leon-Ortiz P, Rodriguez-Mayoral O, Jung-Cook H, et al. Prefrontal and striatal gamma-aminobutyric acid levels and the effect of antipsychotic treatment in first-episode psychosis patients. Biol Psychiatry. 2018;83:475\u201383.","journal-title":"Biol Psychiatry"},{"key":"1508_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/schbul\/sbaa156","volume":"47","author":"G McQueen","year":"2021","unstructured":"McQueen G, Sendt KV, Gillespie A, Avila A, Lally J, Vallianatou K, et al. Changes in brain glutamate on switching to Clozapine in treatment-resistant schizophrenia. Schizophr Bull. 2021;47:662\u201371.","journal-title":"Schizophr Bull"},{"key":"1508_CR29","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/npp.2009.94","volume":"34","author":"AC Lahti","year":"2009","unstructured":"Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Cropsey KL. Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology 2009;34:2675\u201390.","journal-title":"Neuropsychopharmacology"},{"key":"1508_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.schres.2019.09.003","volume":"215","author":"H Li","year":"2020","unstructured":"Li H, Ou Y, Liu F, Chen J, Zhao J, Guo W, et al. Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis. Schizophr Res. 2020;215:337\u201343.","journal-title":"Schizophr Res"},{"key":"1508_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/npp.2013.305","volume":"39","author":"JA Hadley","year":"2014","unstructured":"Hadley JA, Nenert R, Kraguljac NV, Bolding MS, White DM, Skidmore FM, et al. Ventral tegmental area\/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology 2014;39:1020\u201330.","journal-title":"Neuropsychopharmacology"},{"key":"1508_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441\u201349.","journal-title":"Am J Psychiatry"},{"key":"1508_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"1508_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/bmj.312.7027.345","volume":"312","author":"R Kemp","year":"1996","unstructured":"Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996;312:345\u20139.","journal-title":"BMJ"},{"key":"1508_CR35","doi-asserted-by":"publisher","first-page":"e4484","DOI":"10.1002\/nbm.4484","volume":"34","author":"A Lin","year":"2021","unstructured":"Lin A, Andronesi O, Bogner W, Choi IY, Coello E, Cudalbu C, et al. Minimum Reporting Standards for in vivo Magnetic Resonance Spectroscopy (MRSinMRS): Experts\u2019 consensus recommendations. NMR Biomed. 2021;34:e4484.","journal-title":"NMR Biomed"},{"key":"1508_CR36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mrm.1910300604","volume":"30","author":"SW Provencher","year":"1993","unstructured":"Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn ResonMed. 1993;30:672\u201379.","journal-title":"Magn ResonMed"},{"key":"1508_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/mrm.1910300405","volume":"30","author":"R Kreis","year":"1993","unstructured":"Kreis R, Ernst T, Ross BD. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med. 1993;30:424\u201337.","journal-title":"Magn Reson Med"},{"key":"1508_CR38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/mrm.20901","volume":"55","author":"C Gasparovic","year":"2006","unstructured":"Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, Mullins PG, et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med. 2006;55:1219\u201326.","journal-title":"Magn Reson Med"},{"key":"1508_CR39","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","volume":"32","author":"S Leucht","year":"2007","unstructured":"Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining \u2018response\u2019 in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007;32:1903\u201310.","journal-title":"Neuropsychopharmacology"},{"key":"1508_CR40","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","volume":"102","author":"BJ Kinon","year":"2008","unstructured":"Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230\u201340.","journal-title":"Schizophr Res"},{"key":"1508_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.psychres.2010.11.017","volume":"187","author":"VL Stauffer","year":"2011","unstructured":"Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011;187:42\u20138.","journal-title":"Psychiatry Res"},{"key":"1508_CR42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/JCP.0b013e3181d2193c","volume":"30","author":"EM Derks","year":"2010","unstructured":"Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS, Group ES. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol. 2010;30:176\u201380.","journal-title":"J Clin Psychopharmacol"},{"key":"1508_CR43","doi-asserted-by":"crossref","unstructured":"Goldstein ME, Anderson VM, Pillai A, Kydd RR, Russell BR. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18:pyu117.","DOI":"10.1093\/ijnp\/pyu117"},{"key":"1508_CR44","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41380-020-0704-x","volume":"25","author":"K Dempster","year":"2020","unstructured":"Dempster K, Jeon P, MacKinley M, Williamson P, Theberge J, Palaniyappan L. Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. Mol Psychiatry. 2020;25:1640\u201350.","journal-title":"Mol Psychiatry"},{"key":"1508_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1073\/pnas.0135058100","volume":"100","author":"MD Greicius","year":"2003","unstructured":"Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA. 2003;100:253\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1508_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrn1704","volume":"6","author":"BA Vogt","year":"2005","unstructured":"Vogt BA. Pain and emotion interactions in subregions of the cingulate gyrus. Nat Rev Neurosci. 2005;6:533\u201344.","journal-title":"Nat Rev Neurosci"},{"key":"1508_CR47","doi-asserted-by":"publisher","first-page":"12698","DOI":"10.1523\/JNEUROSCI.1758-13.2013","volume":"33","author":"W Dou","year":"2013","unstructured":"Dou W, Palomero-Gallagher N, van Tol MJ, Kaufmann J, Zhong K, Bernstein HG, et al. Systematic regional variations of GABA, glutamine, and glutamate concentrations follow receptor fingerprints of human cingulate cortex. J Neurosci. 2013;33:12698\u2013704.","journal-title":"J Neurosci"},{"key":"1508_CR48","doi-asserted-by":"crossref","unstructured":"Li M, Danyeli LV, Colic L, Wagner G, Smesny S, Chand T, et al. The differential association between local neurotransmitter levels and whole-brain resting-state functional connectivity in two distinct cingulate cortex subregions. Hum Brain Mapp. 2022;43:2833\u201344.","DOI":"10.1002\/hbm.25819"},{"key":"1508_CR49","doi-asserted-by":"publisher","first-page":"102631","DOI":"10.1016\/j.nicl.2021.102631","volume":"30","author":"CM Horne","year":"2021","unstructured":"Horne CM, Vanes LD, Verneuil T, Mouchlianitis E, Szentgyorgyi T, Averbeck B, et al. Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia. NeuroImage Clin. 2021;30:102631.","journal-title":"NeuroImage Clin"},{"key":"1508_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","volume":"73","author":"K Merritt","year":"2016","unstructured":"Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry. 2016;73:665\u201374.","journal-title":"JAMA Psychiatry"},{"key":"1508_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.schres.2018.12.028","volume":"210","author":"NV Kraguljac","year":"2019","unstructured":"Kraguljac NV, Morgan CJ, Reid MA, White DM, Jindal RD, Sivaraman S, et al. A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia. Schizophr Res. 2019;210:239\u201344.","journal-title":"Schizophr Res"},{"key":"1508_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0700-6","volume":"10","author":"B Birur","year":"2020","unstructured":"Birur B, Kraguljac NV, VerHoef L, Morgan CJ, Jindal RD, Reid MA, et al. Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients. Transl psychiatry. 2020;10:15.","journal-title":"Transl psychiatry"},{"key":"1508_CR53","doi-asserted-by":"publisher","first-page":"sgaa072","DOI":"10.1093\/schizbullopen\/sgaa072","volume":"2","author":"P Jeon","year":"2021","unstructured":"Jeon P, Limongi R, Ford SD, Mackinley M, Dempster K, Theberge J, et al. Progressive changes in glutamate concentration in early stages of schizophrenia: a longitudinal 7-Tesla MRS study. Schizophr Bull Open. 2021;2:sgaa072.","journal-title":"Schizophr Bull Open"},{"key":"1508_CR54","first-page":"325","volume":"191","author":"J Theberge","year":"2007","unstructured":"Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. BrJPsychiatry. 2007;191:325\u201334.","journal-title":"BrJPsychiatry"},{"key":"1508_CR55","first-page":"1943","volume":"8","author":"GA McLoughlin","year":"2009","unstructured":"McLoughlin GA, Ma D, Tsang TM, Jones DN, Cilia J, Hill MD, et al. Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. JProteomeRes. 2009;8:1943\u201352.","journal-title":"JProteomeRes"},{"key":"1508_CR56","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/mrm.27742","volume":"82","author":"M Wilson","year":"2019","unstructured":"Wilson M, Andronesi O, Barker PB, Bartha R, Bizzi A, Bolan PJ, et al. Methodological consensus on clinical proton MRS of the brain: Review and recommendations. Magn Reson Med. 2019;82:527\u201350.","journal-title":"Magn Reson Med"},{"key":"1508_CR57","doi-asserted-by":"crossref","unstructured":"Jelen LA, King S, Mullins PG, Stone JM. Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia. J Psychopharmacol. 2018;32:497\u2013508.","DOI":"10.1177\/0269881117747579"},{"key":"1508_CR58","doi-asserted-by":"publisher","first-page":"681419","DOI":"10.3389\/fpsyt.2021.681419","volume":"12","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Lythgoe DJ, Jackson JB, Howard MA, Stone JM, Egerton A. Imaging brain glx dynamics in response to pressure pain stimulation: A (1)H-fMRS Study. Front psychiatry. 2021;12:681419.","journal-title":"Front psychiatry"},{"key":"1508_CR59","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","volume":"5","author":"RS Kahn","year":"2018","unstructured":"Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5:797\u2013807.","journal-title":"Lancet Psychiatry"},{"key":"1508_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1176\/appi.ajp.2015.14121571","volume":"173","author":"DK Sarpal","year":"2016","unstructured":"Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt KH, John M, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry. 2016;173:69\u201377.","journal-title":"Am J Psychiatry"},{"key":"1508_CR61","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0925-4927(97)00057-7","volume":"76","author":"VM Rodriguez","year":"1997","unstructured":"Rodriguez VM, Andree RM, Castejon MJ, Zamora ML, Alvaro PC, Delgado JL, et al. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res. 1997;76:51\u201361.","journal-title":"Psychiatry Res"},{"key":"1508_CR62","doi-asserted-by":"crossref","unstructured":"Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Turkheimer FE, et al. Determinants of treatment response in first-episode psychosis: an (18)F-DOPA PET study. Mol Psychiatry. 2019;24:1502\u201312.","DOI":"10.1038\/s41380-018-0042-4"},{"key":"1508_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291721004128","volume":"52","author":"E Millgate","year":"2022","unstructured":"Millgate E, Hide O, Lawrie SM, Murray RM, MacCabe JH, Kravariti E. Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. Psychological Med. 2022;52:1\u201313.","journal-title":"Psychological Med"},{"key":"1508_CR64","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S2215-0366(16)30171-7","volume":"3","author":"N Koutsouleris","year":"2016","unstructured":"Koutsouleris N, Kahn RS, Chekroud AM, Leucht S, Falkai P, Wobrock T, et al. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. lancet Psychiatry. 2016;3:935\u201346.","journal-title":"lancet Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01508-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T12:06:24Z","timestamp":1674129984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01508-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1508"],"URL":"https:\/\/doi.org\/10.1038\/s41386-022-01508-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1753398\/v1","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.D.H. has a patent for the use of dopaminergic imaging. The remaining authors have no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}